ArticleNeurology(R) neuroimmunology & neuroinflammation2024
Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Neurological Manifestations of Long COVID: Current Evidence, Emerging Concepts, and Future Perspectives.Journal of clinical medicine · 2026Review
- Article
- Review
- Pathogenic IgG from long COVID patients with neurological sequelae triggers sensitive but not cognitive impairments upon transfer into mice.Acta neuropathologica · 2026Article
- Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities.Frontiers in medicine · 2026Review
- Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting.Frontiers in medicine · 2026Article
- Assessment of Nociception and Inflammatory/Tissue Damage Biomarkers in a Post-COVID-19 Animal Model.International journal of molecular sciences · 2025Article
- The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study.Scientific reports · 2025Article
- COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy.Clinical reviews in allergy & immunology · 2025Review
- Immunoglobulins are beneficial in SARS-CoV-2 vaccine-induced small fibre neuropathy even 3 years after onset.Journal of family medicine and primary care · 2025Article
- Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025Review
- Uncovering Hidden Profiles: From Pain-Centric to Multi-Symptom Small Fiber Neuropathy.European journal of neurology · 2025Article
- Autonomic neuropathy is associated with an increase in type-1 cytokines in people living with HIV.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Autonomic Neuropathy Is Associated with An Increase in Type-1 Cytokines in People Living With HIV.bioRxiv : the preprint server for biology · 2025Article
- Post-COVID-19 Small Fiber Neuropathy as a New Emerging Quality of Life-Threatening Disease: A Systematic Review.Microorganisms · 2025Review
- Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Long-Term Neurologic Complications of COVID-19: A Practical Overview The authors present an overview of the presentation and management of common neurologic symptoms associated with long COVID.Practical neurology (Fort Washington, Pa.) · 2024Article
- Long COVID Is Not a Functional Neurologic Disorder.Journal of personalized medicine · 2024Review
- Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment.
methodsA retrospective chart review was conducted on patients seen in the NeuroCOVID Clinic at Yale who developed new-onset SFN after a documented COVID-19 illness. We collected demographics, symptoms, skin biopsy, iCPET testing, treatments, and clinical response to treatment or no intervention.
resultsSixteen patients were diagnosed with SFN on skin biopsy (median age 47, 75% female, 75% White). 92% of patients reported postexertional malaise characteristic of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and 7 patients underwent iCPET, which demonstrated neurovascular dysregulation and dysautonomia consistent with ME/CFS. Nine patients underwent treatment with IVIG, and 7 were not treated with IVIG. The IVIG group experienced significant clinical response in their neuropathic symptoms (9/9) compared with those who did not receive IVIG (3/7; DISCUSSION: Here, we present preliminary evidence that after COVID-19, SFN is responsive to treatment with IVIG and linked with neurovascular dysregulation and dysautonomia on iCPET. A larger clinical trial is indicated to further demonstrate the clinical utility of IVIG in treating postinfectious SFN. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence. It is a retrospective cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.